1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Verastem, Inc.

Verastem, Inc.

2VSA.F
Verastem, Inc.undefined flagFrankfurt Stock Exchange
3.88
EUR
-0.11
- -
269.22MMarket Cap
Verastem, Inc.
2VSA.F
(Frankfurt Stock Exchange)

Recent

price

3.88

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
4.94
2.81
6.93
0.14
0.16
- -
0.28
0.45
0.6
Revenue per Share
-8.13
-20.45
-21.8
-24.82
-19.32
-11.82
-21.18
-13.38
-24.01
-5.3
-4.9
-4.57
-3.96
-3.66
-3.02
-2.36
Basic EPS, GAAP
-6.02
-14.65
-13.95
-18.29
-15.29
-9.58
-17.9
-18.11
-22.29
-2.62
-3.69
-3.95
-3.92
-2.93
-2.12
-1.85
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-8.58
-29.7
-46.38
-65.58
-66.42
-76.34
-94.68
-69.38
-84.44
-46.37
-45.67
-45.7
-37.4
-26.76
-16.81
-14.61
Book Value per Share
-7.57
57.85
62.14
41.28
34.22
23.46
18.02
18.98
-2.07
9.02
6.02
2.94
2.6
-0.81
0.59
0.8
Tangible Book Value per Share
2
2
2
2
3
3
3
5
6
13
15
16
22
36
69
82
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
27
17
89
2
3
- -
10
31
50
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-354.75
-758.14
-55.76
-2,991.18
-2,809.59
- -
-1,149.56
-550.33
-344.56
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
2
1
- -
- -
- -
- -
1
1
Depreciation Expense
-14
-32
-41
-53
-58
-36
-68
-72
-149
-68
-71
-74
-87
-131
-209
-194
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-271.11
-854.77
-76.51
-3,468.1
-2,843.3
- -
-1,306.37
-677.59
-391.16
Profit Margin (%)
45
55
94
86
101
70
71
216
55
128
87
71
117
64
151
136
Working Capital
- -
- -
- -
- -
- -
- -
15
115
107
22
3
26
41
41
81
79
LT Debt
55
90
117
89
102
72
58
124
7
115
88
47
57
-29
57
82
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
5
6
6
LT Borrowings
84
81
77
LT Finance Leases
- -
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
78
88
Market Capitalization
529
474
431

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
154
223
203
Cash, Cash Equivalents & STI
138
214
182
Accounts Receivable, Net
7
- -
10
Inventories
2
2
2
Total Current Liabilities
60
72
67
Payables & Accruals
47
56
53
ST Debt
5
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
98.12%
-99.43%
-297.96%
Free Cash Flow
27.13%
35.22%
40.4%
Net Income, GAAP
24.43%
27.41%
60.35%
Sales/Revenue/Turnover
- -
- -
209.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
10
- -
- -
10
2025
- -
2
11
18
31
2026
19
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.26
-0.31
-0.6
- -
-3.66
2025
-0.96
-0.39
- -
- -
-3.02
2026
-0.37
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Sigilon Therapeutics, Inc. (SGTX)
Proteonomix, Inc. (PROT)
Adlai Nortye Ltd. (ANL)
Gritstone bio, Inc. (GRTS)
Affymax, Inc. (AFFY)
Shandong Boan Biotechnology Co., Ltd. (6955.HK)
Business
Verastem, Inc. (NASDAQ: VSTM), doing business as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing novel small molecule therapies targeting the RAS/MAPK pathway in cancers, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition; its lead approved combination product, avutometinib (AVMAPKI, VS-6766), a RAF/MEK clamp, and defactinib (FAKZYNJA), a FAK inhibitor, received U.S. FDA approval in 2025 for recurrent KRAS-mutant low-grade serous ovarian cancer (LGSOC) under the brand AVMAPKI FAKZYNJA CO-PACK; the company advances additional pipeline candidates in RAS/MAPK-driven solid tumors such as non-small cell lung cancer (NSCLC) and other KRAS-mutant cancers through ongoing Phase 3 (RAMP 301) and Phase 2 trials. Verastem Oncology operates primarily in the United States with a global clinical trial footprint, targeting patients with recurrent and aggressive cancers associated with RAS pathway alterations that affect nearly one-third of all cancers. Founded in 2010 and headquartered in Needham, Massachusetts, the company sold its previous asset duvelisib to Secura Bio, refocused on the RAS/MAPK franchise, announced debt refinancing and a $7.5 million stock purchase with Oberland Capital in January 2025, and entered a strategic commercialization partnership with IQVIA to support the mid-2025 launch of avutometinib plus defactinib; additional collaborations include Chugai Pharmaceutical, GenFleet Therapeutics (with Phase 1/2a data updates for VS-7375 in 2025), Pfizer, and Amgen to enhance research and global reach.